{"Clinical Trial ID": "NCT00828074", "Intervention": ["INTERVENTION 1:", "Phase I: Level 1 dose - Vinorelbine at 20mg/m^2", "- Vinorelbine 20 mg/m^2 per week intravenously (IV) on days 1, 8, 15 and sorafenib 200 mg orally (p.o.) twice daily for 28 days", "INTERVENTION 2:", "Phase I: Dose Level 2 - Vinorelbine at 25mg/m^2", "\u00b7 Vinorelbine 25 mg/m^2 per week intravenously (IV) on days 1, 8, 15 and sorafenib 200 mg orally (p.o.) twice daily for 28 days"], "Eligibility": ["Incorporation criteria:", "Patients should have a stage IV breast adenocarcinoma confirmed histologically or cytologically; (unless metastatic disease is documented by calculated tomography [CT], magnetic resonance imaging [MRI] or bone scan; also, a skin disease that has not been biopsy may be used if, according to clinical researchers, this represents metastatic disease)", "Patients must have a measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (the longest diameter to record) as >20 mm with conventional techniques or >10 mm with spiral scan", "\u2022 Prior radiation therapy is permitted, prior hormone therapy is allowed; the total number of patients who have already received trastuzumab therapy will not exceed 10; no more than 50% of enrolled patients will receive a third line treatment.", "Life expectancy > 6 months", "Performance Status: Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2", "Hemoglobin >= 9.0 g/dl", "Absolute number of neutrophils (ANC) >= 1500/mm^3", "Number of platelets >= 100 000/mm^3", "Total Bilirubin = < 1.5 times ULN", "Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = < 2.5 times the upper limit of normal (ULN) (= < 5 x ULN for patients with hepatic impairment)", "Creatinine = < 1.5 times ULN", "A standard international report (RIN) < 1.5 or a time of prothrombin (PT)/part-time thromboplastin (TPT) within normal limits; patients receiving anti-coagulation therapy with an agent such as warfarin or heparin may be allowed to participate; for patients on warfarin, INR should be measured prior to initiation of sorafenib and monitored at least once a week, or according to the local standard of care, until INR is stable.", "Women of childbearing potential and men must agree to use adequate contraception (hormonal method or birth control barrier; abstinence) prior to entry into the study and for the duration of participation in the study; women of childbearing potential must undergo a negative serum pregnancy test within 7 days of initiation of treatment; if a woman is pregnant or suspects that she is pregnant while participating in the study, she must immediately inform her attending physician.", "Capacity to understand and willingness to sign a written informed consent document", "- Exclusion criteria:", "Patients who have undergone chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin C) before entering the study or those who have not recovered adverse reactions from agents administered more than 4 weeks prior to entering the study; patients who have had bevacizumab within 4 weeks prior to entering the study are allowed.", "Patients cannot receive other experimental agents", "Patients with known brain metastases are excluded from this clinical trial; patients with neurological symptoms must undergo a brain scan/mRI to exclude brain metastases.", "\u00b7 Uncontrolled intercurrent disease including, but not limited to, continuous or active infection (> Common terminology criteria for adverse events [CTCAE] grade 2), symptomatic congestive heart failure, unstable angina, myocardial infarction in the past six months, cardiac ventricular arrhythmias requiring antiarrhythmic treatment, or psychiatric or social situations that would limit compliance with study requirements", "Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management", "- Thrombolic or embolic events such as stroke including transient ischemic seizures in the last 6 months", "- Lung haemorrhage/haemorrhage event >= CATAE Grade 2 within 4 weeks of the first dose of the drug under study", "Any other bleeding or bleeding event >= CTCAE Grade 3 within 4 weeks of the first dose of the drug under study", "Serious non-healing injury, ulcer or bone fracture", "Evidence or history of diathesis or bleeding coagulopathy", "\u2022 Major surgery, open biopsy or severe traumatic injury within 4 weeks of the first study", "Use of St John's wort or rifampin (rifampicin)", "A known or suspected allergy to sorafenib or any given agent in this trial", "Pregnant women", "Human immunodeficiency virus (HIV) patients", "Any condition that impairs the patient's ability to swallow whole pills", "Any problem of malabsorption", "Patients who have received anterior sunitinib are excluded"], "Results": ["Performance measures:", "Number of participants with at least one dose limiting toxicity in Phase I", "Dose Limiting Toxicity (DLT) defined as any treatment-related non-haematological toxicity (excluding alopecia, controllable nausea and vomiting and serum triglycerides < 1,500 mg/dL that recover within one week), grade 4 or higher thrombocytopenia, grade 4 or higher febrile neutropenia requiring hospitalization, or > 2 weeks delay due to toxicity not resolved during the first treatment cycle.", "Duration: 4 weeks from the start of treatment, up to 2 years", "Results 1:", "Title of arm/group: Phase I: Dose Level 1 - Vinorelbine at 20mg/m^2", "Description of the arm/group: Vinorelbine 20mg/m^2 per week intravenously (IV) on days 1, 8, 15 and sorafenib 200 mg orally (p.o.) twice daily for 28 days", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measurement: participants with DLT 0", "Results 2:", "Title of arm/group: Phase I: Dose Level 2 - Vinorelbine at 25mg/m^2", "Description of the arm/group: Vinorelbine 25 mg/m^2 per week intravenously (IV) on days 1, 8, 15 and sorafenib 200 mg orally (p.o.) twice daily for 28 days", "Total number of participants analysed: 5", "Type of measurement: Number", "Unit of measurement: participants with DLT 3"], "Adverse Events": ["Undesirable Events 1:", "Total: 15/41 (36.59 per cent)", "Febrile neutropenia * 0/41 (0.00 %)", "Diarrhoea * 1/41 (2.44%)", "Stomach pain * 1/41 (2.44%)", "Fever * 2/41 (4.88 per cent)", "Cytokine release syndrome * 1/41 (2.44%)", "Infection * 1/41 (2.44 per cent)", "Skin infection * 2/41 (4.88 %)", "urinary infection * 1/41 (2.44%)", "Coagulopathy * 0/41 (0.00 %)", "Increase in INR * 0/41 (0.00 %)", "Increased lipase * 1/41 (2.44%)", "Adverse Events 2:", "Total: 2/5 (40.00 per cent)", "Febrile neutropenia * 1/5 (20.00%)", "Diarrhoea * 0/5 (0.00 %)", "Gastrointestinal pain * 0/5 (0.00 %)", "Fever * 0/5 (0.00 %)", "Cytokine release syndrome * 0/5 (0.00 %)", "Infection * 0/5 (0.00 %)", "Skin infection * 0/5 (0.00 %)", "urinary infection * 0/5 (0.00 %)", "Coagulopathy * 1/5 (20.00%)", "* 1/5 (20.00%)", "Increased lipase * 0/5 (0.00 %)"]}